Accelerating Novel Diagnostic Solutions for Alzheimer’s Disease
Innovating the Future of Alzheimer’s Care at the center of Diagnosis
The ALZpath difference
ALZpath provides diagnostic tools and expertise in Alzheimer’s disease. We believe that with timely and accurate diagnosis, targeted treatments, and support it is possible to improve outcomes for patients and those living with risk of Alzheimer’s disease.
Blood-based biomarker (pTau217) for the early diagnosis of Alzheimer’s disease
Innovative diagnostic tools for various contexts of use
Track over time the impact of a treatment or the progression of an individual’s Alzheimer’s disease
Clinical trial and emerging therapies screening and stratification
A timely and accessible diagnosis
Our novel and proprietary diagnostic blood test is the only commercially available test for phosphorylated tau 217 (pTau217). We offer an approach to diagnosis that is:
- Simple
- Accessible
- Timely
- Cost-effective
- Less invasive
pTau217 can be measured in blood to gain valuable information about what is occurring in the brain. This powerful diagnostic tool can identify key markers of Alzheimer’s disease in the brain prior to the onset of cognitive symptoms.
ALZpath Named 2025 BRONZE Edison Award Winner for its Proprietary pTau217 Antibody
April 7, 2025
ALZpath announced it has been honored with the Bronze Edison Best New Product award. ALZpath’s pTau217 antibody, utilized in a wide range of commercially available blood tests, enables highly sensitive and accurate detection of pTau217, a key Alzheimer’s disease pathology biomarker, well before symptoms appear.
ALZpath pTau217 Data Unveiled at AD/PD™ 2025
April 1, 2025
Data Showcasing ALZpath’s Proprietary pTau217 Antibody at AD/PD™ 2025 Demonstrates High Rate of Reliability and Scalability for Alzheimer’s Disease Research and Diagnosis. Findings from Studies on Blood Tests Utilizing the ALZpath pTau217 Antibody – Integral to Many Advanced Assays for Research and Clinical Use – Featured in Seven Oral Presentations and Two Posters.
ALZpath Adds Biotech Veteran to Board of Directors and Names Prominent Global Researcher as Distinguished Scientific Advisor
March 25, 2025
ALZpath appoints Samantha Budd Haeberlein, PhD, to its Board of Directors and the expanded advisory role of Henrik Zetterberg, MD, PhD, who will now serve as Distinguished Science Advisor. They join a multidisciplinary group of scientific and industry leaders on ALZpath’s Board and Advisory Board.
ALZpath Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025
March 18, 2025
ALZpath has been recognized by Fast Company as one of the World’s Most Innovative Companies of 2025. This honor highlights ALZpath’s impact in advancing accessible, accurate, and early Alzheimer’s diagnostics through its pTau217 blood-based assay, which is integrated into leading diagnostic platforms worldwide.
